Aeroseb-Dex, Decaderm, Decadron, Decaspray, Deronil , Dexameth, Dexamethasone Intensol, Dexasone, Dexone, Hexadrol, Maxidex, Mymethasone, Oradexon
Dalalone D. P., Dalalone-LA, Decadron-LA, Decaject-LA, Dexacen LA-8, Dexasone-LA, Dexo-LA, Dexon LA, Dexone LA, Solurex-LA
DEXAMETHASONE SODIUM PHOSPHATE
AK-Dex, Alba Dex, Dalalone, Decadrol, Decadron Phosphate, Decaject, Dex-4, Dexacen-4, Dexasone, Dexon, Dexone, Hexadrol Phosphate, Maxidex Ophthalmic, Savacort-D, Solurex
Classifications: hormones and synthetic substitutes, adrenal corticosteroid; glucocorticoid; steroid
Pregnancy Category: C
Dexamethasone 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg tablets; 0.5 mg/5 mL, 0.5 mg/0.5 mg oral solution; 0.01%, 0.04% topical aerosol; Dexamethasone Acetate 8 mg/mL, 16 mg/mL injection suspension; Dexamethasone Sodium Phosphate 4 mg/mL, 10 mg/mL, 20 mg/mL, 24 mg/mL injection; 0.1% cream; 0.1% ophthalmic solution, suspension; 0.05% ophthalmic ointment
Long-acting synthetic adrenocorticoid with intense antiinflammatory (glucocorticoid) activity and minimal mineralocorticoid activity. Antiinflammatory action: Prevents accumulation of inflammatory cells at sites of infection; inhibits phagocytosis, lysosomal enzyme release, and synthesis of selected chemical mediators of inflammation; reduces capillary dilation and permeability. Immunosuppression: Not clearly understood, but may be due to prevention or suppression of delayed hypersensitivity immune reaction.
Drug has antiinflammatory and immunosuppression properties.
Adrenal insufficiency concomitantly with a mineralocorticoid; inflammatory conditions, allergic states, collagen diseases, hematologic disorders, cerebral edema, and addisonian shock. Also palliative treatment of neoplastic disease, as adjunctive short-term therapy in acute rheumatic disorders and GI diseases, and as a diagnostic test for Cushing's syndrome and for differential diagnosis of adrenal hyperplasia and adrenal adenoma.
As an antiemetic in cancer chemotherapy; as a diagnostic test for endogenous depression; and to prevent hyaline membrane disease in premature infants.
Systemic fungal infection, acute infections, active or resting tuberculosis, vaccinia, varicella, administration of live virus vaccines (to patient, family members), latent or active amebiasis. Ophthalmic use: Primary open-angle glaucoma, eye infections, superficial ocular herpes simplex, keratitis and tuberculosis of eye. Safe use during pregnancy (category C), lactation, or in children is not established.
Stromal herpes simplex, keratitis, GI ulceration, renal disease, diabetes mellitus, hypothyroidism, myasthenia gravis, CHF, cirrhosis, psychic disorders, seizures.
|Allergies, Inflammation, Neoplasias
Adult: PO 0.254 mg b.i.d. to q.i.d. IM 816 mg q13 wk or 0.81.6 mg intralesional q13 wk
Child: PO/IV/IM 0.080.3 mg/kg/d divided q612h
Adult: IV 10 mg followed by 4 mg q4h, reduce dose after 24 d then taper over 57 d
Child: PO/IV/IM 12 mg/kg loading dose, then 11.5 mg/kg/d divided q46h (max: 16 mg/d)
Adult: IV 16 mg/kg as a single dose or 40 mg repeated q26h if needed
Dexamethasone Suppression Test
Adult: PO 0.5 mg q6h for 48 h
Adult/Child: Ophthalmic/Topical/Inhalation/Intranasal See Appendix A.
PREPARE: Direct: Give undiluted. Intermittent: Dilute in D5W or NS for infusion.
ADMINISTER: Direct: Give direct IV push over 30 sec or less. Intermittent: Set rate as prescribed or according to amount of solution to infuse.
INCOMPATIBILITIES Solution/additive: Daunorubicin, doxorubicin, doxapram, glycopyrrolate, metaraminol, vancomycin.
Dexamethasone suppression test for endogenous depression: false-positive results may be caused by alcohol, glutethimide, meprobamate; false-negative results may be caused by high doses of benzodiazepines (e.g., chlordiazepoxide and cyproheptadine), long-term glucocorticoid treatment, indomethacin, ephedrine, estrogens or hepatic enzyme-inducing agents (phenytoin) may also cause false-positive results in test for Cushing's syndrome.
Assessment & Drug Effects
Patient & Family Education